Stephen Liu, MD, on Key Takeaways From the ARROW Trial of Pralsetinib for RET+ NSCLCJuly 24th 2021
At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.
Stephen Liu, MD, on the Potential Treatment Impact of Amivantamab Plus Lazertinib in EGFR+ NSCLC at ASCO 2021July 13th 2021
At ASCO 2021, Stephen Liu, MD, talked about treating patients with EGFR-mutant non–small cell lung cancer in the post-osimertinib setting with the combination of amivantamab and Lazertinib.
Stephen V. Liu, MD, Discussed the Importance of Testing for Oncogenic Drivers in Frontline NSCLCJune 4th 2021
CancerNetwork® sat down with Stephen V. Liu, MD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about pralsetinib for patients with non–small cell lung cancer harboring RET fusions and adequate biomarker testing in the frontline.